ICER Publishes Evidence Report on Digital Therapeutics for Opioid Use Disorder The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of three digital health technologies (DHTs) […]
Cystic Fibrosis Drug Pricing Violates Human Rights According to Patients
In an unusual move, a coalition of cystic fibrosis patients and their families have filed a complaint with the United Nations, arguing that Vertex Pharmaceuticals (VRTX) is harming patient rights through prohibitive pricing and distribution policies for its life-saving medicines. Specifically, […]
[On-demand Video] Secondary Data First
Secondary data sourced from routinely collected healthcare information is playing a decisive role in stakeholder decision making. Learn how this data is accessed today, which database is right for your purposes, and the key steps to consider to optimize your studies from planning to execution. In […]
COVID-19 and Influenza to be Initial Focus of Google Health Studies App
Google is upping its focus on health research with a new mobile app that lets smartphone users participate in virtual health studies. The tech giant announced Wednesday its new Google Health Studies app with an initial focus on respiratory illnesses, including influenza and COVID-19. The new Google […]
Trump’s Last Ditch Effort to Change Rx Price Rules
The Trump administration’s 11th hour attempt to bring down high prescription drug costs succeeded in drawing swift condemnation from health care stakeholders who frequently find themselves at odds. The finalization last month of two rules intended to ease the financial burden on patients was […]
What’s Driving Oncology HTAs in South Korea?
Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA. To help pharma companies plan clinical trials and economic evidence submission in order to achieve […]
Google Launches Health Studies App
Google made a major move into health research on Wednesday, unveiling a new smartphone app that lets Android users participate in medical studies remotely. The app, called Google Health Studies, could enable the tech giant to better position itself against competitor Apple, which has rolled out […]
Outrage Over Google’s Firing of AI Ethicist Timnit Gebru
Google abruptly fired Timnit Gebru last night, an AI ethicist who has tremendous respect around the world for her work on racial bias in algorithms. Gebru, who was the co-lead of Google’s ethical AI team, announced her firing in a series of tweets on Wednesday. The news was immediately met with […]
Reshaping of Global Policy by COVID: Implications for Market Access
The COVID-19 pandemic has upended daily lives around the globe and has also created new challenges for life sciences companies and governments alike in their mission to ensure effective treatments are both developed and available to patients in need. At a time of uncertainty, governments around the […]
Virtual ISPOR 2021 Issue Panel & Workshop Proposals Due Next Week!
Submit by Wednesday, December 16 for an Opportunity to Present Your Research at Virtual ISPOR 2021! Due to the constraints of the current global environment, ISPOR has extended the deadline for issue panel and workshop proposals to December 16 to allow those interested in speaking at Virtual ISPOR […]
Delays in Clinical Trials Present Pharma Companies With Opportunities to Evolve
COVID-19 has upended clinical trial timelines – putting billions of forecasted sales at risk and delaying getting life-saving treatments to patients. This analysis from Garima Kaul, Senior Director, Research and Insights, Decision Resources Group, part of Clarivate, and Jamie Munro, Executive […]
[Webinar] Tumor Profiling for Health Insurance Providers
On December 10, 2020 1:00 PM – 2:00 PM ET, Illumina will host a webinar on comprehensive genomic profiling (CGP). CGP of tumors is an important aspect of determining therapy for individuals with advanced cancer. It is covered by Medicare for patients with advanced cancers seeking further cancer […]
Using Real World Data to Close the Rare Disease Gap
7,000. That’s the estimated number of distinct types of rare and genetic diseases affecting more than 400 million people around the world. Yet 95% of rare diseases lack an FDA-approved product for treatment.1 Even with the Orphan Drug Act, there are many daunting barriers that stand between […]
[Webinar] Setting the Agenda for #46
On December 9, 4pm CST, Optum will host a webinar focusing on healthcare-related issues that will be in the forefront in the next few months as President Donald Trump looks to leave his mark through executive orders, the Supreme Court considers the fate of the Affordable Care Act and Congress […]
Data on a Mission: Removing Barriers to Understanding of Rare Disease
Research and drug development for rare and genetic diseases is challenging without insight into history and clinical manifestations. Missing efficacy endpoints and underrepresentation in medical coding systems further hinder our understanding of rare disease. Real-world data (RWD) closes this data […]
Healthcare Artificial Intelligence Market: Global Forecast to 2027
Report Highlights: The global healthcare artificial intelligence (AI) market is expected to grow at a CAGR of 41.4% from 2020 to 2027 to reach $51.3 billion by 2027. The healthcare artificial intelligence market study presents historical market data in terms of value (2019), estimated […]
Six Payer Executives to Watch in 2021
The past year has forced health plans to nimbly adapt to the demands of a global pandemic, including massive spikes in demand for telehealth and new therapies—and soon, vaccines—coming to market. These changes, especially the now-larger market for virtual visits and digital care, are likely to carry […]
Improving Peer Review in Economics
Three experimental economists, Gary Charness (UCSB), Anna Dreber (SSE) and Severine Toussaert (Oxford), are conducting a 15-20 min anonymous survey on peer review in economics. So far, more than 1,000 researchers have completed the survey and they would like to invite you to participate if you […]
Response to NICE Methods of Health Technology Evaluation
NICE recently posted a consultation entitled "The NICE methods of health technology evaluation: the case for change". which detailed its proposals for reviewing and/or updating its methods. It sets out 5 areas of work with 56 separate proposals listed separately across these sections. These […]
New Healthcare Venture from Uber Health’s Dan Trigub
Trigub and co-founder Inna Plumb have launched MedArrive as a new care management platform that enables healthcare providers and payers to extend services into the home. The startup bridges the virtual care gap by integrating physician-led telemedicine with hands-on care from a network of trusted […]
ICER Analytics™ Accelerates Real-World Application of ICER Reports
The Institute for Clinical and Economic Review (ICER) today formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices, and explore new ways to apply […]
Disruption and Transformation in the COVID Era: 5 Pharma Trends for 2021
The prospective pharmaceutical industry trends first identified by Tribeca Knowledge in late 2019 were all pre-COVID, even though they continue to unfold. Now, the COVID-19 pandemic has eclipsed every other development in healthcare and pharmaceuticals during 2020. It will likely do so next year as […]
AMCP Nexus 2020: The Specialty Pharmacy Pipeline
The specialty pharmaceutical market is continuing to see increased competition, and in the past 10 years, there has been a significant number of new options to treat patients with several specialty conditions. During a session at AMCP Nexus 2020 Virtual, Aimee Tharaldson, PharmD, senior clinical […]
Innovative Payments, Management are Needed for Cell and Gene Therapies
Cell and gene therapies are a transformative approach that provides new therapeutic options for patients with cancer, immune disorders, hemophilia, and other conditions. However, these therapies present fundamental challenges for payers seeking to balance access, cost, and affordability. During a […]
MMIT Partners With Leading Patient Access Hubs
Understanding market access is hard. Tracking shifts in coverage and payer policies for pharmaceutical products is even harder. MMIT partners with leading patient access hubs to provide them with a competitive advantage, supported by the industry leader in patient access information and insights. […]
Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Little is known about when and what types of real-world evidence (RWE) studies inform pharmacy and therapeutic (P&T) committee decisions. To address this gap in knowledge, researchers evaluated evidence sources cited in P&T committee monographs and therapeutic class reviews and assessed the […]
CMS Announces Drug Payment Reductions with the “Most Favored Nation” Effective January 1, 2021
Centers for Medicare and Medicaid Services (CMS) announced the long-awaited seven year Most Favored Nation (MFN) model as an interim final rule. Published in the Federal Register on Nov. 27, the rule will potentially decrease payment for 50 expensive drugs provided in hospital outpatient departments […]
Reimbursing Innovative and Potentially Curative Gene and Cell Therapies
In this feature, following his participation in a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting (Virtual ISPOR Asia Pacific 2020; 14–16 September), Sean Sullivan (University of Washington, WA, USA) discusses payment approaches that […]
Government, Big Pharma, and The People: A Century of Dis-Ease
It can be said that society shapes our values toward drugs and drugs shape society. And while drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. spends so much on health care. Even though pharmaceuticals account for a relatively small share of […]
Biden Defers to Experts on COVID-19 Vaccine Prioritization
There will likely be a limited supply of coronavirus vaccine doses available immediately after a vaccine is authorized by the US Food and Drug Administration, and because risk for Covid-19 can vary among different groups of people, prioritizing the vaccine poses challenges. Therefore, […]
